Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair (Trigger-lap)

October 16, 2017 updated by: mads u werner, University of Copenhagen

Trigger-point Blockade in Persistent Pain After Laparoscopically Assisted Groin Hernia Repair

Groin hernia repair is a common procedure performed in approximately 2,000 patients per one million inhabitants. Severe chronic pain following groin hernia repair is seen in 2-5% of the patients indicating that a large number of patients each year suffer from debilitating reduction in health-related quality of life.

This study examines the effect of ultra-sound guided blocks with local anesthesia in the groin in regard to pain relief and sleep quality.

The hypothesis of the study is that a block will confer significant pain relief to patients with severe chronic pain following laparoscopical groin hernia repair.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This placebo-controlled, randomized, double-blind, cross-over study in subjects with severe pain after laparoscopically assisted groin hernia repair, examines the effect of an ultra-sound guided local anesthetic block of a trigger-point, situated near the spermatic cord at the superficial inguinal ring.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2100
        • Multidisciplinary Pain Center, Neuroscience Center, Copenhagen University Hospital, DENMARK

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with persistent pain (< 6 mo) after laparoscopical groin hernia repair
  • Patients with maximal pain area 3 cm or less from the superficial inguinal ring
  • Patients living in the Capital Region of Denmark (Region Hovedstaden) or the Region of Zealand (Region Sjælland)

Exclusion Criteria:

  • Known allergy to bupivacaine or other local anesthetics of amide-type
  • Declared incapable of making his/hers own affairs
  • Does not comprehend Danish in writing or speech
  • Cognitive impairment to a degree influencing the testing reliability
  • Known recurrence of the inguinal hernia
  • Other surgical procedures performed in the groin or on the external genitals
  • Neuropathy affecting the groin region caused by other conditions, e.g. post-stroke, multiple sclerosis, herniated intervertebral disc
  • Abuse of alcohol or drugs
  • Unable to cooperate with the sensory examinations

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active drug
10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
injection, once, 5 min
Other Names:
  • Bupivacain "SAD"
  • 0.9% Sodium-chloride
Placebo Comparator: Placebo
10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
injection, once, 5 min
Other Names:
  • Bupivacain "SAD"
  • 0.9% Sodium-chloride

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Normalized summed pain intensity differences (SPID)
Time Frame: 20 min
The number of patients with normalized summed pain intensity differences (SPID) of more or equal to 50% after bupivacaine AND SPID less or equal to 25% after placebo.
20 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Thermal thresholds
Time Frame: 20 min
Quantitative changes in thermal thresholds (warmth detection threshold, cool detection thresholds, heat pain threshold) after bupivacaine compared to placebo
20 min
Suprathreshold heat stimulation
Time Frame: 20 min
Quantitative changes in pain rating to suprathreshold heat stimulation after bupivacaine compared to placebo
20 min
Pressure pain thresholds
Time Frame: 20 min
Quantitative changes in pain rating to pressure algometry stimulation after bupivacaine compared to placebo
20 min
Sensory mapping
Time Frame: 20 min
Quantitative changes in area of cool hypoesthesia assessed by a thermal roller after bupivacaine compared to placebo
20 min
Pain questionnaire
Time Frame: 7 days
Quantitative changes in summed pain intensity differences (SPIDs) assessed morning and evening after bupivacaine compared to placebo
7 days
Sleep quality questionnaire
Time Frame: 7 days
Quantitative changes in sleep quality assessed each morning after bupivacaine compared to placebo
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mads Werner, Multidisciplinary Pain Center, Neuroscience Center, Rigshospitalet, Copenhagen University Hospital, DENMARK
  • Study Chair: Henrik Kehlet, MD, DMSc, Section of Surgical Pathophysiology, Juliane Marie Center, Copenhagen University Hospital, DENMARK

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2013

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

February 15, 2014

First Submitted That Met QC Criteria

February 18, 2014

First Posted (Estimate)

February 19, 2014

Study Record Updates

Last Update Posted (Actual)

October 18, 2017

Last Update Submitted That Met QC Criteria

October 16, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Data will be submitted as supplementary material in the final manuscript

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on Bupivacaine

3
Subscribe